Autosomal-recessive agammaglobulinemia is a rare and heterogeneous disorder, characterized by early-onset infections, profound hypogammaglobulinemia of all immunoglobulin isotypes and absence of circulating B lymphocytes. To investigate the molecular basis of the disease, 23 patients with early-onset disease and no mutations in Bruton tyrosine kinase, the gene responsible for X-linked agammaglobulinemia, were selected and analyzed by direct sequencing of candidate genes. Two novel mutations in the m heavy chain (mHC) gene (IGHM) were identified in three patients belonging to two unrelated families. A fourth patient carries a previously described G4A nucleotide substitution at the À1 position of an alternative splice site in IGHM; here, we demonstrate that this mutation is indeed responsible for aberrant splicing. Comparison of bone marrow cytofluorimetric profiles in two patients carrying different mutations in the IGHM gene suggests a genotype-phenotype correlation with the stage at which B-cell development is blocked. Several new single nucleotide polymorphisms (SNPs) both in the mHC and in the l5-like/VpreB-coding genes were identified. Two unrelated patients carry compound heterozygous variations in the VpreB1 gene that may be involved in disease ethiology.
Introduction
Early B-cell development is a highly regulated process, taking place in the bone marrow. The transition from the pro-B-cell to the pre-B-cell stage is defined by sequential immunoglobulin gene rearrangements and surface expression of the pre-B-cell receptor (pre-BCR) complex containing the m heavy chain (mHC), Iga/Igb heterodimers and the surrogate light chains (SLC) (VpreB/l5). 1 Various studies have investigated the different steps and the transcription factors involved in this phase of B-cell development. 2 The checkpoint at the pre-BCR level is required for the following VJ L rearrangement that allows the assembly of the mature B-cell receptor (BCR) -composed of mHC, light chain, and the Iga/Igb heterodimeric signal-transducing elements -and its expression on the surface of newly formed immature B cells. 3 The correct expression and signaling activity of the BCR are required for normal B-cell development. Accordingly, mutations in the genes required for BCR assembly or for its signaling cascade, severely impair B-cell development in the bone marrow, causing X-linked and autosomalrecessive forms of agammaglobulinemia in humans, characterized by low/absent serum immunoglobulin levels and absence of circulating B cells. 4 Mutations in the gene coding for the Bruton tyrosine kinase (Btk), a cytoplasmic protein that mediates BCR signaling, were found to be responsible for X-linked agammaglobulinemia (XLA). 5, 6 In XLA, B-cell development in the bone marrow is blocked at the pro-B-to pre-B-cell stage. 7, 8 However, even though XLA accounts for 85-90% of all cases of agammablobulinemia, a small group of patients have a block of B-cell development without evidence of BTK mutations. The family trees of these patients are suggestive of an autosomal-recessive form of agammaglobulinemia. The crucial role of BCR signaling for B-cell development and the phenotype of animal models point to the genes encoding for components of the pre-BCR as promising candidate genes for autosomal-recessive forms of agammaglobulinemia. In fact, a mouse knockout model demonstrates that mHC is essential for B-cell development; lack of mHC causes a specific block at the pro-B-to pre-B-cell stage and a severe reduction of B-cell number in the periphery. 9 Four point mutations, a 2-bp deletion and few large deletions of the human mHC gene (IGHM) have been identified previously by genetic analysis in patients with autosomal-recessive forms of agammaglobulinemia. 10, 11 Another member of the pre-BCR complex -the l5 genewas also knocked out in the mouse, resulting in a leaky phenotype with a specific block at the pre-B-cell stage of differentiation; however, 4-months-old mice retain 20% of peripheral B cells and show a normal capability to mount an antibody response to both T-dependent and T-independent antigens. 12 In humans, a single case of compound heterozygote mutations in the l5/14.1 gene was associated with classical autosomal-recessive agammaglobulinemia, 13 emphasizing the fact that mutations in the same gene often affect B-cell development and functionality to different extents in humans and mice.
Finally, knockout models of the last two components of the pre-BCR complex, CD79a and CD79b, 14, 15 provide evidence for their requirement in B-cell differentiation in the bone marrow, in particular in the V-DJ rearrangement process. Recently, two patients were found to have homozygous defects in Iga: 16, 17 comparison with mHCdeficient patients reveals, in both cases, a block at the early stages of B-cell development and similarly impaired V-DJ rearrangements. 16 In this study, 23 Italian patients diagnosed with agammaglobulinemia (11 females and 12 males for whom mutations in BTK were excluded) were analyzed for mutations in each of the genes encoding for the pre-BCR proteins. We identified one previously known mutation and two novel mutations in the coding region of the IGHM gene and several new genetic polymorphisms (single nucleotide polymorphisms (SNPs)) in the IGHM and VpreB/l5 genes.
Results

Patient selection
A total of 23 patients, from the Italian Association of Pediatric Hematology and Oncology (AIEOP)-Italian Network of Primary Immunodeficiencies (IPINET) database, were selected for this study. They belong to 22 unrelated families where they represent sporadic cases, with the exception of patients P21 and P22 that are siblings. History of consanguinity has not been reported in any of the patients.
Before this study, sequence analysis of the BTK gene was performed on 123 out of 128 male patients present in the XLA registry: BTK mutations were found in 103 patients (comprising all familiar cases and 86 sporadic cases).
We analyzed 13 out of 20 male patients with no mutations in BTK gene and 10 female patients already assigned to the autosomal-recessive agammaglobulinemia subregistry. The remaining seven male patients were excluded form this study because either deceased or untraceable. Patients previously subjected to similar genetic screenings in other laboratories were excluded. Table 1 summarizes the main clinical features of these patients, showing absent or nearly absent counts of circulating B cells.
The genetic analysis was performed by polymerase chain reaction (PCR) amplification and direct DNA sequencing of all exons from the genes encoding the five proteins of the pre-BCR: six exons of mHC gene (IGHM), three exons of l5-like gene (IGLL1), two exons of VpreB gene (VpreB1), five exons of Iga gene (mb-1) and six exons of Igb gene (B29).
The mHC gene (IGHM) is mutated in agammaglobulinemic patients Four patients (P15, P17, P21 and P22) from three unrelated families were found to carry homozygous mutations in the mHC gene (IGHM). In all cases, both healthy parents were heterozygous carriers of the mutation, although none of the families had a known history of consanguinity. Figure 1 summarizes the results of the IGHM screening: two novel mutations were identified in three patients belonging to two families. First, P17 is homozygous for a complex 5-bp deletion and 3-bp insertion at codon 377 in exon 4, leading to a frameshift and a premature stop codon after seven amino Pre-BCR mutations in autosomal-recessive agammaglobulinemia S Ferrari et al acids. Second, P21 and P22 are siblings carrying a homozygous 1-bp deletion in exon 3, an 'A' deletion at codon 246. This mutation causes frameshift and premature termination after three amino acids. In these three patients, both the secreted and membrane forms of the mHC protein are predicted to be missing.
The G4A single base transition at codon 433 within exon 4 found in P15 is a previously known mutation described by Yel et al. 10 and Granados et al. 11 It affects the À1 position of the alternative splice site required for the production of the membrane-bound isoform of the protein and, in addition, it causes a glycine to serine substitution in the secreted isoform. It has been assumed that the mutation impairs the alternative splicing required to encode the membrane isoform of the mHC, but its actual effect on RNA splicing has not yet been demonstrated experimentally.
To establish the effect of the G4A (Gly433Ser) mutation, we analyzed the expression of the alternatively spliced IGHM mRNA species in bone marrow cells obtained from patients P15 (carrying the Gly433Ser mutation), P17 carrying the new IGHM mutation described above, P9 who shows a pro-B-cell differentiation block (determined by cytofluorimetric analysis of the bone marrow, data not shown) due to an unknown genetic defect, and a healthy donor.
Reverse transcription was performed on total RNA extracted from bone marrow cells. Semi-quantitative PCR was performed using primers specific for the secreted and the membrane form respectively, as shown schematically in Figure 2a Figure 2 shows that the mRNA corresponding to the secreted isoform of mHC is present in all the patients analyzed, even though its amount is generally lower than that in healthy controls. The different levels of mHC expression may reflect the smaller number of CD19-positive B-cell precursors in the bone marrow of these subjects; a subsequent assessment of the expression levels of the CD19 marker by Real-time PCR proved that this is indeed the case (Figure 2c ).
The mRNA corresponding to the membrane isoform is present in samples P9 and P17. In sample P15, on the other hand, the only product amplified by the specific Pre-BCR mutations in autosomal-recessive agammaglobulinemia S Ferrari et al primers is about 150 bp larger than the expected 250-bplong fragment. Direct sequence analysis of the mutant cDNA product from P15 shows an insertion of 137 nucleotides (from nucleotide 1956 to 2092 of the reference sequence X57331). The insertion seen in the mutant is due to highly efficient usage of a cryptic GT-donor site within intron 4 that causes the inclusion in the mRNA of the 5 0 portion of intron 4. The novel transcript contains the sequence specific for the secreted isoform of mHC and an extra portion of intron 4 ( Figure 2) . Thus, the net effect on mHC of the mutation at the alternative splice site of intron 4 in P15, is that only the secreted isoform with a Gly433Ser missense substitution is present in the patient, while synthesis of the membrane isoform is completely abolished.
Single nucleotide polymorphisms of IGHM gene
Previous studies have established that the IGHM locus is highly polymorphic. 11 In our study, we identified 16 intragenic SNPs, including three novel SNPs and 13 SNPs described already in the NCBI SNPs database and/ or in Granados et al.
11 (Table 2 ). These nucleotide variations occurred either outside or inside the coding region; the latter contains both silent and missense variants. Unless stated otherwise, all SNPs were heterozygous. The frequency of the IGHM gene polymorphisms found in our group of patients were compared to the caucasian population frequencies published in the NCBI database, when available, or to the frequencies calculated in our laboratory from a control group of healthy individuals (indicated with a in Table 2 ). Two of the novel SNPs (variants 8 and 9 in Table 2 ) are also found in control individuals. This is generally true for all the SNPs observed in the patients' population, where their allelic frequencies do not significantly differ from the expected frequencies calculated in normal individuals. Two notable exceptions are variant 1 that is significantly more frequent in the patients' population (Po0.01), and variant 7 that was not found in 184 chromosomes from healthy Italian donors.
It is noteworthy that patient P5, in addition to variants 8 and 9, carries eight rare SNPs simultaneously. Two of them, S190G and V214G, are present in homozygous state. The same 10 SNPs are also present in the patients' mother, with the main difference that she is heterozygous for both S190G and V214G. Due to the lack of a bone marrow biopsy from this patient, we could not assess if this unusual SNPs pattern has any consequence on the expression of the mHC. l5 (IGLL1) and VpreB (VpreB1) genes The four patients (P15, P17, P21 and P22) with mutations in the IGHM gene were excluded from further screening of the other pre-BCR genes, while the remaining 19 patients were analyzed for the presence of mutations in the l5-and VpreB-coding genes (IGLL1 and VpreB1).
The so-called SLCs l5-like and VpreB are key components of the pre-BCR protein complex: the human Pre-BCR mutations in autosomal-recessive agammaglobulinemia S Ferrari et al l5-like coding gene was mutated in one instance of autosomal-recessive agammaglobulinemia. 13 Furthermore, mice lacking the VpreB proteins show a block of the B-cell differentiation at the pre-B-cell stage. 18, 19 Table 3 summarizes the SNPs identified in our patients' population. We found several new variants in the VpreB1 and IGLL1 genes that are also present in healthy subjects with frequencies not significantly different form that found in patients.
Patients P1 and P14 are compound heterozygous for 5 0 À62/D76N and 5 0 À97/S122L mutations in VpreB1; in addition, patient P23 carries the V33M variation on one allele of IGLL1 gene and the three polimorphisms at codon 92 and 94 in exon 2 and at codon 183 in exon 3 on the other allele. Since the frequency of all these alleles in the general population is rather low, it cannot be ruled out that these variations contribute to the disease ethiology.
Iga and Igb genes
Sequence analysis of the Iga-coding gene (mb-1) did not show the presence of nucleotide variations in any of the patients.
Analysis of the Igb gene (B29) showed that all patients are carriers, in one or both alleles, of the haplotype represented by the two following SNPs: a T4C silent change at codon 122 in exon 3, and a 3 0 -UTR þ 89 T4C transition.
The allelic frequencies of these polymorphisms in the patients' population were similar to those reported in the NCBI SNPs database.
Cytofluorimetric analysis of bone marrow B-cell precursors
The prevailing view of B-cell lineage commitment identifies three phenotypes based on the expression of cell-surface markers: cells go through a CD34 þ / CD19À/CD10 þ early pro-B-cell stage to become Indicates the frequencies of the newly identified variants, calculated in our laboratory from healthy subjects.
Pre-BCR mutations in autosomal-recessive agammaglobulinemia S Ferrari et al CD34 þ /CD19 þ /CD10 þ late pro-B cells, followed by the CD34À/CD19 þ /CD10 þ pre-B-cell stage of development. The use of surface markers to define the lineage affiliation and the differentiation stage of CD34 þ progenitors provides a preliminary characterization of eventual blocks of B-cell development. We compared the bone marrow of an XLA patient with the bone marrow obtained from two patients carrying mutations in the IGHM gene (P15 and P17).
Three-color staining of gated lymphoid cells with antibodies to CD34, CD19 and CD10 showed that in the bone marrow of the mHC-deficient patient P15, as well as in the bone marrow of the XLA subject, the majority of CD34 þ cells are CD19 positive, indicating that in these patients the late pro-B-cell precursors are present and accumulate (Figure 3a) . In contrast, the immunological profile of the mHC-deficient patient P17 shows that most CD34 þ cells are CD19 negative, while only few pro-Bcell precursors are present (0.11%). Accordingly, Realtime PCR analysis performed on mRNA extracted from total bone marrow cells, confirmed that expression of CD19 in the bone marrow of P17 is more severely impaired than in P15 (Figure 2c ). In both mHC-deficient patients, as well as in the XLA patient, the CD34 þ / CD19 þ pro-B-cell precursors are also CD10 þ . The evidence of different pro-B-cell profiles in patients P15 (CD34 þ /CD19 þ /CD10 þ typical of late pro-B cells) and P17 (CD34 þ /CD19À/CD10 þ /À typical of earlier maturation stages) suggests a link between the phenotype of B-cell precursors and the severity of the mutation in the IGHM gene (Figure 3b and c) .
Discussion
This study reports the comprehensive genetic analysis of the pre-BCR in 23 Italian patients affected by autosomalrecessive agammaglobulinemia. This mode of inheritance is rare compared to the more frequent X-linked agammaglobulinemia; in fact, our patients constitute the second largest reported population after the collection of patients described in Granados et al.
11
Among the five genes screened by complete sequence analysis of exons and exon/intron boundaries, two novel mutations in the mHC gene were found in three patients belonging to two different families. P17 is homozygous for a complex 5-bp deletion À3-bp insertion in exon 4. P21 and P22 are siblings with a homozygous 1-bp deletion in exon 3. Both mutations cause frameshifts and premature termination and, as a consequence, both the secreted and the membrane isoforms of mHC are predicted to be absent. The healthy parents of the patients in these two families are not aware of any degree of consanguinity; in each case, the mutated alleles show an identical haplotype, indicating that a founder effect may be involved. A third homozygous mutation in the mHC gene, corresponding to a single base pair substitution at the -1 position of the alternative splice site in exon 4, was detected in patient P15. This mutation is recurrent in patients from different countries and immunoglobulin haplotypes. 11 In the present study, we have directly analyzed how this mutation interferes with the splicing process, showing that usage of a cryptic GT-donor site within intron 4 of the mutant mHC gene generates a novel transcript bearing an insertion of 137 nucleotides derived from intronic sequences. In principle, if the cryptic site had occurred upstream of the secreted isoform STOP codon, it would generate an aberrant mHC isoform (fusing the secreted and membrane isoform sequences). Our data provide formal proof that the G4A mutation at codon 433 completely abolishes the synthesis of the membrane isoform of the mHC, as further confirmed by cytofluorimetric analysis of the bone marrow from P15, where mHC is absent from the surface of B-cell precursors (data not shown), and define the molecular mechanism of this disease causing mutation.
The frequency of mHC mutations in our cohort (4/23) is similar to that reported by Granados et al.
11 (20-30%) , taking into account that two families registered in the Italian database were excluded from this study because they had been described previously as carriers of a Gly433Ser mutation (F11 and F12 in Granados et al.
). It should be noted that a source of uncertainty and possibly underestimation of the mutation rate arises in rare cases, such as in patient P5, where the simultaneous presence of 10 rare SNPs on one allele and two rare SNPs on the other, may alter the expression of functional mHC at the level of mRNA or protein. Unfortunately the compound effect of polymorphic variants is difficult to assess, especially when a bone marrow biopsy is not available, such as in this case. In total, 16 SNPs were identified within the mHC gene, three of which are novel (indicated with a in Table 2 ). Three SNPs cause an amino acid substitution (D76E, S190G and V214G) within the loops linking the b strands of the immunoglobulin domain. It is unlikely that any of these substitutions has deleterious consequences on the protein structure since the loops are poorly conserved either in humans or mice. As mentioned above, the outcome of the simultaneous occurrence of two or three of these amino-acid changes -patient P5 is heterozygous for D76E and homozygous for S190G and V214G -is harder to predict.
In addition, it is well known that variations within exons, either missense or silent, may interfere with mRNA processing. 20 Several examples of exonic ciselements important for correct splice-site identification and distinct from the classical splicing signals have been described. These elements can act both by stimulating (enhancers) or by repressing (silencers) splicing. Exonic splicing enhancers (ESEs), in particular, are crucial for efficient recognition of intron-exon junctions. The ESE Finder algorithm (http://rulai.cshl.edu/tools/ESE/) predicts a difference in the pattern of ESEs distribution in exon 1 of the mHC gene depending on the presence of the polymorphism at codon 20 (variant 1). Notably, according to the SNPs frequencies calculated in our laboratory, this variant is significantly more frequent in the patients' population than in healthy individuals. Three patients (P7, P11 and P16) carry this SNP on one allele and P11 also carries variant 8. Owing to the unavailability of bone marrow samples from P11, we do not know if the presence of these two SNPs influences the efficiency of mRNA splicing.
Finally, the mutation frequency of mHC, as well as of the other genes of the pre-BCR, may be underestimated owing to our sequencing strategy that addresses exons and adjacent intronic and UTR regions but would not detect additional variations in the promoter and/or introns of the gene.
Several SNPs have also been detected in the VpreB1 gene. Two of them (5 0 À62 and 5 0 À97) map in the promoter region of the gene, but fall outside the known transcription factor-binding sites. 21 SNP (5 0 À97) is present in P14 together with the S122L amino-acid change that is predicted to have an impact on the protein structure. SNP (5 0 À62) is present in two patients (P1 and P18). P1 also carries an amino acidic change in exon 1 (D76N), which should be neutral with respect to the protein structure as determined by the PolyPhen software. Further work will be required to understand if any of these SNPs is actually a disease-causing mutation. Once again, the lack of bone marrow biopsies, as in the case of P5 and P11, hampers the analysis of mRNAs and proteins.
Assembly of a functional pre-BCR is considered a major checkpoint for B-cell differentiation taking place in the bone marrow. An early block of this process occurs in patients with mutations in BTK, mHC, Iga and l5-like.
To explore if different mutations in mHC could give rise to subtle differences at the level of the B-cell development in the bone marrow, we analyzed two patients (P15 and P17). Specifically, we asked if the cell phenotype from complete knock out of mHC (P17) differs from the one where the mHC secreted isoform, bearing a S4G missense mutation, is still present (P15). We performed a side-by-side analysis of B-cell populations in P15 and P17, compared to an XLA patient. We confirmed that the pre-B-cell subset (CD34-CD19 þ ) is nearly absent in all patients. This finding was expected and further reinforces the notion that B-cell development does not progress beyond the pre-BCR checkpoint in both forms of agammaglobulinemia. Interestingly, the precursor profiles differ between P15 and P17, with an increased number of CD34 þ CD19ÀCD10 þ /À precursor cells in P17, suggesting that a block at an earlier pro-B-cell stage may occur in this patient. It is possible that the different phenotype observed in P15 and P17 may be due to factors unrelated to the IGHM mutation, such as the genetic background, age and immunological status of the patients that are hard to estimate due to the rarity of patients and bone marrow biopsies. Nevertheless, further functional studies of the mutated proteins may confirm the specificity of this developmental block and elucidate the underlying molecular mechanism.
After completion of this screen focused on the pre-BCR genes, we also analyzed the patients' DNA for mutations in the BNLK gene, based on the finding that a defect in BNLK was identified in a single patient with agammaglobulinemia. 22 BLNK is normal in all patients of our cohort, therefore, the causative genetic defect must involve novel genes in about 80% of the recessive agammaglobulinemia cases.
Materials and methods
Registry of patients with agammaglobulinemia
The AIEOP-IPINET, was established in 1999 with the aim to provide all patients on the national territory with clinical assistance based on shared updated diagnostic and therapeutical recommendations. Furthermore, the AIEOP maintains an electronic database (registry) of all patients, organized according to their clinical features and genetic diagnosis. In the case of agammaglobulinemia, male patients are initially assigned to the XLA registry. Female patients and the male patients from the XLA registry that do not have mutations in the BTK gene are grouped as putative autosomal-recessive agammaglobulinemia cases.
Mutational analysis
Genomic DNA was extracted from peripheral blood leukocytes using standard techniques. Complete sequence analysis of the five genes coding for the pre-BCR was performed by PCR amplification of exons and exon/intron junctions (FastStart Taq DNA Polymerase, Roche Diagnostics, GmbH, Mannheim, Germany) under standard conditions. PCR products were purified (PCR Cleanup Plates, Millipore, Carrigtwohill, Co. Cork, Ireland) and sequenced on both strands with Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Warrington, Cheshire, UK) and run on an ABI 3730 Genetic Analyzer (Applied Biosystems). Each new polymorphism was confirmed by sequencing of at least 89 healthy unrelated controls. The sequence information for primers used in this study is available upon request. The reference sequences used in this study are X57331 (IGHM gene), M27749 (IGLL1), S74019 (VpreB1), M80462 (mb-1) and M89957 (B29 gene).
Transcripts analysis
Total RNA was isolated from bone marrow mononuclear cells, using RNeasy Mini Kit (Qiagen, GmbH, Hilden, Germany). A total of 1-2 mg RNA was reverse-transcribed into cDNA using Oligo-dT primers and SuperScript II (Invitrogen, Carlsbad, CA, USA). PCR for the secreted isoform of mHC was performed with primers specific forward (SF) (5 0 -GCCACTGAAGCAGAC CATCT-3 0 ) and specific reverse (SR) (5 0 -ATGACCAGG GACACGTTGTA-3 0 ). The membrane mHC isoform was amplified by MF 5 0 -GTGCAGTGGATGCAGAGG-3 0 and MR 5 0 -TCTCAAAGCCCTCCTCGT-3 0 . PCR products were analyzed by standard gel electrophoresis. b-actin was used as internal control.
Real-time PCR analysis was performed with iCycler iQ detection system (Biorad, Richmond, CA, USA) using the TaqMan R Gene Expression assay for CD19 mRNA (Assay_on_Demand Hs00221068_m1) and standard software for quantification as recommended by the manufacturer. CD19 gene expression levels were normalized to the expression level of b-actin mRNA determined for each sample. Comparative quantitation between patients and healthy donor was carried out using the 2 ÀDDCt method (ABI User Bulletin #2). The relative values of CD19 were expressed as the percentage of the expression levels of CD19 in patients with respect to the expression level of CD19 in the healthy donor, set at 100%.
Cytofluorimetric analysis
Bone marrow mononuclear cells isolated by FicollHypaque gradient centrifugation were stained with the following conjugated anti-human monoclonal antibodies: FITC-labelled anti-human CD10, PE-labelled antihuman CD34 and PerCP-labelled anti-human CD19 (Becton-Dickinson). Cells were resuspended in phosphate buffer saline (PBS), 0.1% bovine serum albumin (BSA) at the concentration of 5 Â 10 5 -5 Â 10 6 cells/ml and incubated at 41C for 30 min with 10 ml of each conjugated antibody. Three-color stained cells were washed twice with PBS/BSA and analyzed on a FACSCalibur flow cytometer (Becton-Dickinson).
